MSD Polska urges value-based evaluation of modern therapies for Polish economy

MSD Polska, the Polish arm of Merck, advocates shifting evaluation of modern therapies from cost to value delivered to patients, society, and the Polish economy. This signals a policy push likely aimed at influencing upcoming drug reimbursement decisions in Poland. The impact depends on whether Polish health authorities adopt value-based frameworks, which could affect market access for innovative treatments.